Literature DB >> 10048414

Leukemia arising out of paroxysmal nocturnal hemoglobinuria.

J W Harris1, R Koscick, H M Lazarus, J R Eshleman, M E Medof.   

Abstract

In paroxysmal nocturnal hemoglobinuria (PNH), one or more hematopoietic stem cells that are defective in GPI anchor assembly as a result of mutation in the PIG-A gene preferentially expand in the bone marrow and give rise to peripheral blood elements that are deficient in GPI anchored protein expression. According to current concepts, 5-15% of PNH patients develop leukocyte dyscrasias which invariably are acute myelogenous leukemia (AML). In this review, the literature from 1962 to the present is analyzed regarding the type of leukocyte dyscrasia, incidence, and cytogenetic features of the abnormal cells that have been reported. Among a total of 119 cases that are well-documented, 104 myeloid dyscrasias involving several categories in addition to AML, as well as 15 lymphoid dyscrasias are described. Of 1,760 patients in 15 series that contain 20 or more patients, 16 (1%) are reported as having developed "acute leukemia." However, of 288 listed as having died, 13 (5%) are recorded as having had "acute leukemia." In 32 of the patients with hematological dyscrasias where karyotypes were analyzed, 7 were found to be normal and 25 found to harbor various alterations with the +8 abnormality present in 8. In 5 of 7 instances evidence indicates that the dyscratic cell arises from the PNH clone. Processes potentially involved in the evolution of the dyscratic cells from PNH clones are discussed.

Entities:  

Mesh:

Year:  1999        PMID: 10048414     DOI: 10.3109/10428199909058399

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  9 in total

Review 1.  Pathogenesis of selective expansion of PNH clones.

Authors:  Hideki Nakakuma; Tatsuya Kawaguchi
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

2.  A classification-based machine learning approach for the analysis of genome-wide expression data.

Authors:  James Lyons-Weiler; Satish Patel; Soumyaroop Bhattacharya
Journal:  Genome Res       Date:  2003-03       Impact factor: 9.043

Review 3.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 4.  Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems.

Authors:  Wendell F Rosse; Junichi Nishimura
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

5.  Acute myelogenous leukemia with PIG-A gene mutation evolved from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome.

Authors:  H Tanaka; N Imamura; N Oguma; T Shintani; K Tanaka; H Hyodo; K Oda; A Kimura
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

6.  Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria.

Authors:  R Chen; S Nagarajan; G M Prince; U Maheshwari; L W Terstappen; D R Kaplan; S L Gerson; J M Albert; D E Dunn; H M Lazarus; M E Medof
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

7.  Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Authors:  Lova Sun; Daria V Babushok
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

8.  The utility of TIPS in the management of Budd-Chiari syndrome.

Authors:  Ernesto P Molmenti; Dorry L Segev; Aravind Arepally; Jenny Hong; Paul J Thuluvath; Rudra Rai; Andrew S Klein
Journal:  Ann Surg       Date:  2005-06       Impact factor: 12.969

9.  Paroxysmal nocturnal hemoglobinuria clone in a case of myelodysplastic syndrome rapidly progressing to acute leukemia.

Authors:  Swati Srivastava; Shano Naseem; Ritu Gupta; Rajesh Kashyap; Rajender Chaudhary
Journal:  Indian J Hematol Blood Transfus       Date:  2009-04-06       Impact factor: 0.900

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.